| Study | Reason for exclusion |
|---|---|
| ADHERE 2017 | SRL not started till day 28 post transplant |
| Barsoum 2007 | Cannot compare SRL with MMF till 3 months or more post transplant |
| CALLISTO 2009 | Compared SRL commenced at transplant with SRL commenced at week 5 |
| Carmellini 2010 | TOR‐I use in stable transplant patients (> 6 months); not primary immunosuppression |
| CENTRAL 2012 | Patient randomised at week 7 |
| CERTITEM 2015 | Randomised at 3 months based on protocol biopsy at 3 months. Therefore not primary Immunosuppression |
| Citterio 2004 | Unclear if this is a RCT |
| Cruzado 2016 | Switch to EVL as secondary immunosuppression more than 1 year post transplant |
| EVIDENCE 2014 | Study of non‐inferiority of steroid withdrawal |
| Fior 2015 | Unclear if this is a RCT |
| Libetta 2007 | Patients selected into study at 3 months; unclear whether RCT |
| Libetta 2015 | Late conversion to SRL |
| Mathew 2006 | Compares same dose of SRL using oral solution or tablets |
| Nafar 2012 | Quasi‐RCT comparing TOR‐I with CNI but TOR‐I not commenced till 3 months post transplant |
| NCT00005113 | Paediatric study terminated due to inability to recruit sufficient patients |
| NCT00965094 | Patients not randomised until month 3 |
| nEVEROLD 2017 | Conversion to TOR‐I at 1 month |
| NEVERWOUND 2014 | Compares immediate with delayed administration of EVL |
| Novoa 2011 | Patients not randomised till 3 months |
| Oh 2012 | EVL commenced at 1 month post transplant |
| Pretagostini 2016 | EVL commenced at 1 month post transplant |
| Rivelli 2014 | Both groups received SRL; dose increased in one group at 3 months when TAC ceased |
| SOCRATES 2014 | EVL not commenced till 14 days post transplant |
| Tamashiro 2017 | Late conversion at 3 months to TOR‐I; not clear whether this is an RCT |
| van Gelder 2003 | Conversion to TOR‐I at 12 months |
| Wojciechowski 2017 | Late conversion to TOR‐I after diagnosis of BK viruria |
| Wyrley‐Birch 2009 | Randomisation between pairs of recipients of kidneys from same donor not groups of recipients |
CNI ‐ calcineurin inhibitor; EVL ‐ everolimus; MMF ‐ mycophenolate mofetil; RCT ‐ randomised controlled trial; SRL ‐ sirolimus; TAC ‐ tacrolimus; TOR‐I ‐ target of rapamycin inhibitor